数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Samuel E. Navarro Director 60 9.28万美元 未持股 2016-04-20
Srini Conjeevaram Director 57 11.45万美元 未持股 2016-04-20
Robert G. Moussa Director 69 12.02万美元 未持股 2016-04-20
Bruce F. Wesson Director 81 11.72万美元 未持股 2016-04-20
Brett D. Hewlett Director 53 10.57万美元 未持股 2016-04-20
Stephen T. Wills Interim Executive Chairman and Principal Executive Officer 59 24.65万美元 未持股 2016-04-20
Amy Paul Director 72 11.35万美元 未持股 2016-04-20

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
John E. Yetter Executive Vice President, Finance and Chief Financial Officer 63 50.67万美元 未持股 2016-04-20
Robert C. Cole Group President, Traditional Wound Care and Corporate Accounts 63 48.89万美元 未持股 2016-04-20
Frederic Eigner Executive Vice President of Operations and General Manager, Derma Sciences Canada Inc. 66 43.77万美元 未持股 2016-04-20
Barry J. Wolfenson Group President, Advanced Wound Care 49 60.12万美元 未持股 2016-04-20
Stephen T. Wills Interim Executive Chairman and Principal Executive Officer 59 24.65万美元 未持股 2016-04-20

董事简历

中英对照 |  中文 |  英文
Samuel E. Navarro

Samuel E. Navarro,2014年3月以来,他曾一直担任我们的董事会成员。2008年10月以来,他一直担任Gravitas Healthcare公司(为医疗技术公司提供战略咨询服务)的管理合伙人。从2005年9月到2008年10月,他曾担任Cowen & Co.(位于纽约)的董事总经理,以及他们的医疗技术投资银行项目负责人,领导高级人团队,并负责建立所有产品类别(并购、咨询和融资服务和产品)的特许经营。从2001年到2005年,他曾任职The Galleon Group,经营the Galleon Healthcare Fund,担任高级投资组合经理。他曾负责所有领域(制药/生物制药行业、医疗技术和医疗用品、医疗服务的所有领域)的卫生保健投资。从1998年7月到2001年2月,他曾担任ING Barings公司的医疗保健投资银行全球主管。他也曾任职于Arstasis公司、Derma Sciences公司、MicroTherapeutics公司、Jomed公司、Photomedex公司、Pixelux Entertainment公司的董事会。他持有The Wharton School at the University of Pennsylvania的财务方向的工商管理硕士学位、Stanford University的工程科学硕士学位、The University of Texas at Austin的工程学士学位。


Samuel E. Navarro has served as our director since June 2019. Mr. Navarro also served as ViralClear's director from April 2020 until July 2020. Mr. Navarro has over 30 years of experience in investment banking, business development and medical technology. He currently serves as managing partner of Gravitas Healthcare, LLC, a strategic advisory/mergers and acquisition firm that specializes in emerging growth medical device companies. Since its founding in 2008 the firm has completed over 30 strategic medical device partnership transactions with some of the largest medical device companies in the industry. From 2005 through 2008 Mr. Navarro served as a managing director and global head of Medical Technology Investment Banking at Cowen & Company. From 2001 through 2005 Mr. Navarro served as a senior investment manager at The Galleon Group running the Galleon Healthcare Fund. From 1998 through 2001 he was global head of Healthcare Investment Banking at ING Barings, and prior to that, he was senior medical technology research analyst at UBS, Furman Selz and Needham & Company. From March 2014 to January 2017 Mr. Navarro served as a board director on the Audit and Nominating and Governance Committees of Derma Sciences, Inc. Since May 2018 Mr. Navarro has been serving on the board of directors of StrataSkin Sciences, Inc. and since 2019 as a member of their Audit Committee. Mr. Navarro serves or has served on the board of directors of other medical device companies, such as Arstasis, Dextera Surgical, Fixes-4-Kids, Jomed, MicroTherapeutics, and one non-medical company, Pixelux Entertainment. Mr. Navarro also served in the past as an advisory board member of OrthoPediatrics. Mr. Navarro received an MBA in finance from The Wharton School at the University of Pennsylvania. He also holds a master's degree in engineering from Stanford University and a bachelor's degree in engineering from the University of Texas at Austin.
Samuel E. Navarro,2014年3月以来,他曾一直担任我们的董事会成员。2008年10月以来,他一直担任Gravitas Healthcare公司(为医疗技术公司提供战略咨询服务)的管理合伙人。从2005年9月到2008年10月,他曾担任Cowen & Co.(位于纽约)的董事总经理,以及他们的医疗技术投资银行项目负责人,领导高级人团队,并负责建立所有产品类别(并购、咨询和融资服务和产品)的特许经营。从2001年到2005年,他曾任职The Galleon Group,经营the Galleon Healthcare Fund,担任高级投资组合经理。他曾负责所有领域(制药/生物制药行业、医疗技术和医疗用品、医疗服务的所有领域)的卫生保健投资。从1998年7月到2001年2月,他曾担任ING Barings公司的医疗保健投资银行全球主管。他也曾任职于Arstasis公司、Derma Sciences公司、MicroTherapeutics公司、Jomed公司、Photomedex公司、Pixelux Entertainment公司的董事会。他持有The Wharton School at the University of Pennsylvania的财务方向的工商管理硕士学位、Stanford University的工程科学硕士学位、The University of Texas at Austin的工程学士学位。
Samuel E. Navarro has served as our director since June 2019. Mr. Navarro also served as ViralClear's director from April 2020 until July 2020. Mr. Navarro has over 30 years of experience in investment banking, business development and medical technology. He currently serves as managing partner of Gravitas Healthcare, LLC, a strategic advisory/mergers and acquisition firm that specializes in emerging growth medical device companies. Since its founding in 2008 the firm has completed over 30 strategic medical device partnership transactions with some of the largest medical device companies in the industry. From 2005 through 2008 Mr. Navarro served as a managing director and global head of Medical Technology Investment Banking at Cowen & Company. From 2001 through 2005 Mr. Navarro served as a senior investment manager at The Galleon Group running the Galleon Healthcare Fund. From 1998 through 2001 he was global head of Healthcare Investment Banking at ING Barings, and prior to that, he was senior medical technology research analyst at UBS, Furman Selz and Needham & Company. From March 2014 to January 2017 Mr. Navarro served as a board director on the Audit and Nominating and Governance Committees of Derma Sciences, Inc. Since May 2018 Mr. Navarro has been serving on the board of directors of StrataSkin Sciences, Inc. and since 2019 as a member of their Audit Committee. Mr. Navarro serves or has served on the board of directors of other medical device companies, such as Arstasis, Dextera Surgical, Fixes-4-Kids, Jomed, MicroTherapeutics, and one non-medical company, Pixelux Entertainment. Mr. Navarro also served in the past as an advisory board member of OrthoPediatrics. Mr. Navarro received an MBA in finance from The Wharton School at the University of Pennsylvania. He also holds a master's degree in engineering from Stanford University and a bachelor's degree in engineering from the University of Texas at Austin.
Srini Conjeevaram

Srini Conjeevaram,从1998年5月起担任Derma Sciences的董事。他是Penumbra, Inc.——一家神经与血管的医疗器械公司的医院关系部副总裁。他也是SC Capital Management, LLC的董事总经理,该公司是管理公司,管理投资于私人医疗公司的增长权益基金。从1991年到2006年3月,他在Galen Associates供职,专司医疗保健增值权益投资,并于1996年成为普通合伙人。在加入Galen Associates之前,1989年到1990年,他是Smith Barney的企业金融助理;从1982年到1987年,他是通用汽车公司(General Motors Corporation)的高级项目工程师。Srini Conjeevaram拥有印度马德拉斯大学(Madras University, India)授予的机械工程学士学位、斯坦福大学(Stanford University)授予的机械工程理学硕士学位和印第安纳大学(Indiana University)授予的工商管理硕士学位。


Srini Conjeevaram has served as a director of Derma Sciences since May 1998. Mr. Conjeevaram is Vice President of Strategic Planning at Penumbra, Inc., a neurovascular medical device company. Mr. Conjeevaram is also Managing Director of SC Capital Management, LLC, a management company that manages growth-equity fund investments in privately-held healthcare companies. From 1991 through March 2006 he was with Galen Partners, focusing on growth equity healthcare investments, becoming a General Partner in 1996. Prior to his affiliation with Galen Partners, he was an Associate in Corporate Finance at Smith Barney from 1989 to 1990 and a Senior Project Engineer for General Motors Corporation from 1982 to 1987. Mr. Conjeevaram earned a Bachelor of Science degree in Mechanical Engineering from Madras University, India, a Master of Science degree in Mechanical Engineering from Stanford University, and a Master of Business Administration from Indiana University.
Srini Conjeevaram,从1998年5月起担任Derma Sciences的董事。他是Penumbra, Inc.——一家神经与血管的医疗器械公司的医院关系部副总裁。他也是SC Capital Management, LLC的董事总经理,该公司是管理公司,管理投资于私人医疗公司的增长权益基金。从1991年到2006年3月,他在Galen Associates供职,专司医疗保健增值权益投资,并于1996年成为普通合伙人。在加入Galen Associates之前,1989年到1990年,他是Smith Barney的企业金融助理;从1982年到1987年,他是通用汽车公司(General Motors Corporation)的高级项目工程师。Srini Conjeevaram拥有印度马德拉斯大学(Madras University, India)授予的机械工程学士学位、斯坦福大学(Stanford University)授予的机械工程理学硕士学位和印第安纳大学(Indiana University)授予的工商管理硕士学位。
Srini Conjeevaram has served as a director of Derma Sciences since May 1998. Mr. Conjeevaram is Vice President of Strategic Planning at Penumbra, Inc., a neurovascular medical device company. Mr. Conjeevaram is also Managing Director of SC Capital Management, LLC, a management company that manages growth-equity fund investments in privately-held healthcare companies. From 1991 through March 2006 he was with Galen Partners, focusing on growth equity healthcare investments, becoming a General Partner in 1996. Prior to his affiliation with Galen Partners, he was an Associate in Corporate Finance at Smith Barney from 1989 to 1990 and a Senior Project Engineer for General Motors Corporation from 1982 to 1987. Mr. Conjeevaram earned a Bachelor of Science degree in Mechanical Engineering from Madras University, India, a Master of Science degree in Mechanical Engineering from Stanford University, and a Master of Business Administration from Indiana University.
Robert G. Moussa

Robert G. Moussa,从2005年5月以来担任Derma Sciences的董事。从2008年2月起,他是Dilon Technologies, Inc.的董事长、总裁兼首席执行官,该公司是一家对早期乳腺癌进行检测的伽马成像系统的制造商。在加入Dilon Technologies, Inc.之前,他担任Moussa & Associates的总裁和首席执行官,该公司是一家服务于制药、生物技术和医疗行业的咨询公司。在成立该公司之前,他曾在密苏里州圣路易斯Mallinckrodt, Inc.担任过多个高管职,该公司是产值达24亿美元的医疗和化工公司。离目前最近他在Mallinckrodt, Inc.担任的职务是1995年到1997年担任公司的国际总裁。之前,从1992年到1996年之前,他担任Mallinckrodt Medical, Inc.——Mallinckrodt, Inc.最大的、收入超过10亿美元的商业部门的总裁兼首席执行官。在加入Mallinckrodt Medical, Inc.之前,从1978年到1992年,Robert G. Moussa担任过Mallinckrodt, Inc.的国际医疗产品集团副总裁、欧洲医疗产品副总裁和总经理、急救护理总经理、业务主管和销售经理。在加入Mallinckrodt, Inc.之前,从1969年到1976年,他在英国Sherwood Medical供职,最近的职务是市场总监。Robert G. Moussa拥有Collége du Sacre——Caur, Beirut, Lebanon于1966年授予的他的学士学位;拥有英国伦敦伊灵大学(Ealing University, London, England)于1969年授予的工商管理学士学位。他还参与过加州大学伯克利分校(University of California at Berkeley)、阿斯彭研究所(Aspen Institute)、沃顿商学院行政学校(Wharton Executive School)、和创造性领导中心(Center for Creative Leadership)的行政研讨会。


Robert G. Moussa has served as a director of Derma Sciences since May 2005. Mr. Moussa is the Chairman, President and Chief Executive Officer of Dilon Technologies, Inc., makers of a gamma imaging system for early breast cancer detection, a position he has held since February 2008. Before joining Dilon Technologies, Inc., Mr. Moussa served as President and Chief Executive Officer of Robert Moussa & Associates, a consulting firm serving the pharmaceutical, biotechnology and healthcare industries. Prior to founding this firm, he served in a variety of executive positions with Mallinckrodt, Inc., St. Louis, Missouri, a $2.4 billion healthcare and chemical company. Mr. Moussa’s most recent assignment at Mallinckrodt, Inc. was President - International, a position he held from 1995 through 1997. Previously, he served from 1992 to 1996 as President and Chief Executive Officer of Mallinckrodt Medical, Inc., Mallinckrodt, Inc.’s largest business unit with over $1 billion in revenues. Before joining Mallinckrodt Medical, Inc., Mr. Moussa served during the period 1978 through 1992 as Mallinckrodt, Inc.’s Group Vice President - International Medical Products, Vice President and General Manager - Medical Products Europe, General Manager - Critical Care, Director of Business Operations and General Sales Manager. Prior to joining Mallinckrodt, Inc., Mr. Moussa held a number of positions during the period from 1969 through 1976 with Sherwood Medical, United Kingdom, most recently as Director of Marketing. Mr. Moussa received his Baccalaureate from the Collége du Sacre-Cœur, Beirut, Lebanon, in 1966 and his Bachelor of Science in Business Administration from Ealing University, London, England, in 1969. He has also completed executive seminars at the University of California at Berkeley, the Aspen Institute, the Wharton Executive School and the Center for Creative Leadership.
Robert G. Moussa,从2005年5月以来担任Derma Sciences的董事。从2008年2月起,他是Dilon Technologies, Inc.的董事长、总裁兼首席执行官,该公司是一家对早期乳腺癌进行检测的伽马成像系统的制造商。在加入Dilon Technologies, Inc.之前,他担任Moussa & Associates的总裁和首席执行官,该公司是一家服务于制药、生物技术和医疗行业的咨询公司。在成立该公司之前,他曾在密苏里州圣路易斯Mallinckrodt, Inc.担任过多个高管职,该公司是产值达24亿美元的医疗和化工公司。离目前最近他在Mallinckrodt, Inc.担任的职务是1995年到1997年担任公司的国际总裁。之前,从1992年到1996年之前,他担任Mallinckrodt Medical, Inc.——Mallinckrodt, Inc.最大的、收入超过10亿美元的商业部门的总裁兼首席执行官。在加入Mallinckrodt Medical, Inc.之前,从1978年到1992年,Robert G. Moussa担任过Mallinckrodt, Inc.的国际医疗产品集团副总裁、欧洲医疗产品副总裁和总经理、急救护理总经理、业务主管和销售经理。在加入Mallinckrodt, Inc.之前,从1969年到1976年,他在英国Sherwood Medical供职,最近的职务是市场总监。Robert G. Moussa拥有Collége du Sacre——Caur, Beirut, Lebanon于1966年授予的他的学士学位;拥有英国伦敦伊灵大学(Ealing University, London, England)于1969年授予的工商管理学士学位。他还参与过加州大学伯克利分校(University of California at Berkeley)、阿斯彭研究所(Aspen Institute)、沃顿商学院行政学校(Wharton Executive School)、和创造性领导中心(Center for Creative Leadership)的行政研讨会。
Robert G. Moussa has served as a director of Derma Sciences since May 2005. Mr. Moussa is the Chairman, President and Chief Executive Officer of Dilon Technologies, Inc., makers of a gamma imaging system for early breast cancer detection, a position he has held since February 2008. Before joining Dilon Technologies, Inc., Mr. Moussa served as President and Chief Executive Officer of Robert Moussa & Associates, a consulting firm serving the pharmaceutical, biotechnology and healthcare industries. Prior to founding this firm, he served in a variety of executive positions with Mallinckrodt, Inc., St. Louis, Missouri, a $2.4 billion healthcare and chemical company. Mr. Moussa’s most recent assignment at Mallinckrodt, Inc. was President - International, a position he held from 1995 through 1997. Previously, he served from 1992 to 1996 as President and Chief Executive Officer of Mallinckrodt Medical, Inc., Mallinckrodt, Inc.’s largest business unit with over $1 billion in revenues. Before joining Mallinckrodt Medical, Inc., Mr. Moussa served during the period 1978 through 1992 as Mallinckrodt, Inc.’s Group Vice President - International Medical Products, Vice President and General Manager - Medical Products Europe, General Manager - Critical Care, Director of Business Operations and General Sales Manager. Prior to joining Mallinckrodt, Inc., Mr. Moussa held a number of positions during the period from 1969 through 1976 with Sherwood Medical, United Kingdom, most recently as Director of Marketing. Mr. Moussa received his Baccalaureate from the Collége du Sacre-Cœur, Beirut, Lebanon, in 1966 and his Bachelor of Science in Business Administration from Ealing University, London, England, in 1969. He has also completed executive seminars at the University of California at Berkeley, the Aspen Institute, the Wharton Executive School and the Center for Creative Leadership.
Bruce F. Wesson

Bruce F. Wesson,是公司的创始董事之一,目前担任董事会首席董事和副主席、审计委员会主席和董事会信息科技委员会成员。他是Galen管理公司(Galen Management)名誉创始合伙人和高级顾问,这是一家医疗保健风险投资公司;从1990年到2011年,他担任该公司常务董事和Galen合伙公司(Galen Partners)普通合伙人。他在Smith Barney,Harris Upham 公司(Harris Upham & Co. Inc.)企业财务部任职23年,这是一家投资银行公司,最近担任该公司高级副总裁和常务董事。在该公司期间,他领导公司大客户群,负责公司许多大型客户事务。他也在公司估值委员会担任主席,这是监管公司产生的所有估计意见的委员会。从1980年到2010年,他在Chemtura公司(Chemtura Corporation)担任董事。他在Acura制药公司(Acura Pharmaceuticals, Inc.)担任董事和薪酬和审计委员会成员,这是一家专业制药公司。另外,他在Derma Sciences公司(Derma Sciences, Inc.)担任董事(从2006年开始),包括副首席董事(从2008年开始),也在该公司薪酬委员会任职,这是一家皮肤病产品制造商;他也在许多私人公司的担任董事。他在科尔盖特大学(Colgate University)得到学士学位,在哥伦比亚大学商学院(Columbia Graduate Business School)得到工商管理硕士学位。


Bruce F. Wesson has been a member of our Board of Directors since March 1998. From January 1991 until June 30 2011 Mr. Wesson was a Partner of Galen Associates, a health care venture firm, and a General Partner of Galen Partners III, L.P. Prior to January 1991 he was Senior Vice President and Managing Director of Smith Barney, Harris Upham & Co. Inc., an investment banking firm. He currently serves on the Boards of Derma Sciences, Inc., and as Vice Chairman of the Board of MedAssets, Inc., each a publicly traded company. Mr. Wesson earned a Bachelor of Arts degree from Colgate University and a Masters of Business Administration from Columbia University.
Bruce F. Wesson,是公司的创始董事之一,目前担任董事会首席董事和副主席、审计委员会主席和董事会信息科技委员会成员。他是Galen管理公司(Galen Management)名誉创始合伙人和高级顾问,这是一家医疗保健风险投资公司;从1990年到2011年,他担任该公司常务董事和Galen合伙公司(Galen Partners)普通合伙人。他在Smith Barney,Harris Upham 公司(Harris Upham & Co. Inc.)企业财务部任职23年,这是一家投资银行公司,最近担任该公司高级副总裁和常务董事。在该公司期间,他领导公司大客户群,负责公司许多大型客户事务。他也在公司估值委员会担任主席,这是监管公司产生的所有估计意见的委员会。从1980年到2010年,他在Chemtura公司(Chemtura Corporation)担任董事。他在Acura制药公司(Acura Pharmaceuticals, Inc.)担任董事和薪酬和审计委员会成员,这是一家专业制药公司。另外,他在Derma Sciences公司(Derma Sciences, Inc.)担任董事(从2006年开始),包括副首席董事(从2008年开始),也在该公司薪酬委员会任职,这是一家皮肤病产品制造商;他也在许多私人公司的担任董事。他在科尔盖特大学(Colgate University)得到学士学位,在哥伦比亚大学商学院(Columbia Graduate Business School)得到工商管理硕士学位。
Bruce F. Wesson has been a member of our Board of Directors since March 1998. From January 1991 until June 30 2011 Mr. Wesson was a Partner of Galen Associates, a health care venture firm, and a General Partner of Galen Partners III, L.P. Prior to January 1991 he was Senior Vice President and Managing Director of Smith Barney, Harris Upham & Co. Inc., an investment banking firm. He currently serves on the Boards of Derma Sciences, Inc., and as Vice Chairman of the Board of MedAssets, Inc., each a publicly traded company. Mr. Wesson earned a Bachelor of Arts degree from Colgate University and a Masters of Business Administration from Columbia University.
Brett D. Hewlett

Brett D. Hewlett,从2010年2月起担任Derma Sciences的董事。从2005年起,他担任Comvita的首席执行官。在加入Comvita,之前,他在Tetra Pak——世界领先的食品包装公司供职达15年,担任过该公司地中海东部市场董事总经理和沙特阿拉伯地区商业主管。他组织和管理自己的咨询公司,并且一直是一个活跃的天使投资人支持在新西兰的初创企业。Brett D. Hewlett拥有新西兰梅西大学(Massey University, New Zealand)于1987年授予的食品技术学士学位和瑞士国际管理发展研究所(International Institute for Management Development, Switzerland)于1993年授予的工商管理硕士学位。


Brett D. Hewlett has served as a director of Derma Sciences since February 2010. Mr. Hewlett served as the Chief Executive Officer of Comvita from 2005 until the end of 2015 and currently serves as an Advisor to the Board of Comvita. He is a Director and member of the Audit and Risk Committees of NZX listed company SeaDragon Ltd. since October 2015 and is Director and Chairman of Priority One (since October 2015), Western Bay of Plenty and Tauranga City Council’s Economic Development Agency. Prior to his affiliation with Comvita, Mr. Hewlett served for fifteen years with Tetra Pak, a world-leading food packaging company, in the capacities of Managing Director for Eastern Mediterranean markets and Commercial Director for Saudi Arabia. He has organized and managed his own consulting company and has been an active angel investor supporting start-up companies in New Zealand. Mr. Hewlett earned a Bachelor of Food Technology degree from Massey University, New Zealand, in 1987 and a Masters of Business Administration degree from International Institute for Management Development, Switzerland, in 1993.
Brett D. Hewlett,从2010年2月起担任Derma Sciences的董事。从2005年起,他担任Comvita的首席执行官。在加入Comvita,之前,他在Tetra Pak——世界领先的食品包装公司供职达15年,担任过该公司地中海东部市场董事总经理和沙特阿拉伯地区商业主管。他组织和管理自己的咨询公司,并且一直是一个活跃的天使投资人支持在新西兰的初创企业。Brett D. Hewlett拥有新西兰梅西大学(Massey University, New Zealand)于1987年授予的食品技术学士学位和瑞士国际管理发展研究所(International Institute for Management Development, Switzerland)于1993年授予的工商管理硕士学位。
Brett D. Hewlett has served as a director of Derma Sciences since February 2010. Mr. Hewlett served as the Chief Executive Officer of Comvita from 2005 until the end of 2015 and currently serves as an Advisor to the Board of Comvita. He is a Director and member of the Audit and Risk Committees of NZX listed company SeaDragon Ltd. since October 2015 and is Director and Chairman of Priority One (since October 2015), Western Bay of Plenty and Tauranga City Council’s Economic Development Agency. Prior to his affiliation with Comvita, Mr. Hewlett served for fifteen years with Tetra Pak, a world-leading food packaging company, in the capacities of Managing Director for Eastern Mediterranean markets and Commercial Director for Saudi Arabia. He has organized and managed his own consulting company and has been an active angel investor supporting start-up companies in New Zealand. Mr. Hewlett earned a Bachelor of Food Technology degree from Massey University, New Zealand, in 1987 and a Masters of Business Administration degree from International Institute for Management Development, Switzerland, in 1993.
Stephen T. Wills

Stephen T. Wills,1997年起,担任副总裁、秘书、财务总管、首席财务官;2005年起,担任运营执行副总裁,直到2011年6月被任命为首席运营官、执行副总裁。1997年7月至2000年8月,他还是Derma Sciences的副总裁、首席财务官,这是一个供应伤口、皮肤护理产品的上市公司,目前担任其首席董事。之前,他曾担任Miami International Securities Exchange, LLC的董事、审核委员会主席,这是私营的全电子化的期权和股票交易所,目前仍在开发中;此前,他曾担任上市公司U.S. Helicopter Corp.的董事。1991年至2000年8月,他是Golomb, Wills & Company, P.C。的总裁、首席运营官,这是一个公共会计公司。他是注册会计师,获得West Chester University的会计学士学位、Temple University的税务硕士学位。


Stephen T. Wills,currently serves as the Chief Financial Officer (since 1997), Chief Operating Officer (since 2011), Treasurer and Secretary, of Palatin. Mr. Wills has served on the board of directors of MediWound Ltd. (Nasdaq: MDWD), a biopharmaceutical company focused on treatment in the fields of severe burns, chronic and other hard to heal wounds, since April 2017, and as Chairman from October 2017 until August 2022, and starting September 2022, is the chairman of the audit committee and a member of the compensation committee. He also has served on the board of directors of Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, since March 2019, and is chairman of the audit committee and a member of the compensation and finance committees. Mr. Wills serves as the Chief Financial Officer of Cactus Acquisition Corp (Nasdaq: CCTS), a Special Purpose Acquisition Company (SPAC). Mr. Wills served on the board of directors of Amryt Pharma Plc, a biopharmaceutical company focused on developing and delivering treatments to help improve the lives of patients with rare and orphan diseases, from September 2019 through April 2023, when Amryt was acquired by Chiesi Farmaceutici. Mr. Wills served on the board of trustees and executive committee of The Hun School of Princeton, a college preparatory day and boarding school since 2014, and as its Chairman starting June 2018, to his retirement in June 2023. Mr. Wills served on the board of directors of Caliper Corporation, a psychological assessment and talent development company, since March 2016, and as Chairman from December 2016 to December 2019, when PSI Corporation acquired Caliper. Mr. Wills served as Executive Chairman and Interim Principal Executive Officer of Derma Sciences, Inc., a provider of advanced wound care products, from December 2015 to February 2017, when Derma Sciences was acquired by Integra Lifesciences (Nasdaq: IART). Previously, Mr. Wills served on the board of directors of Derma Sciences as the lead director and chairperson of the audit committee from June 2000 to December 2015, and served as the Chief Financial Officer of Derma Sciences from 1997 to 2000. Mr. Wills served as the President and Chief Operating Officer of Wills, Owens & Baker, P.C., a public accounting firm, from 1991 to 2000. Mr. Wills, a certified public accountant, earned his Bachelor of Science in accounting from West Chester University, and a Master of Science in taxation from Temple University.
Stephen T. Wills,1997年起,担任副总裁、秘书、财务总管、首席财务官;2005年起,担任运营执行副总裁,直到2011年6月被任命为首席运营官、执行副总裁。1997年7月至2000年8月,他还是Derma Sciences的副总裁、首席财务官,这是一个供应伤口、皮肤护理产品的上市公司,目前担任其首席董事。之前,他曾担任Miami International Securities Exchange, LLC的董事、审核委员会主席,这是私营的全电子化的期权和股票交易所,目前仍在开发中;此前,他曾担任上市公司U.S. Helicopter Corp.的董事。1991年至2000年8月,他是Golomb, Wills & Company, P.C。的总裁、首席运营官,这是一个公共会计公司。他是注册会计师,获得West Chester University的会计学士学位、Temple University的税务硕士学位。
Stephen T. Wills,currently serves as the Chief Financial Officer (since 1997), Chief Operating Officer (since 2011), Treasurer and Secretary, of Palatin. Mr. Wills has served on the board of directors of MediWound Ltd. (Nasdaq: MDWD), a biopharmaceutical company focused on treatment in the fields of severe burns, chronic and other hard to heal wounds, since April 2017, and as Chairman from October 2017 until August 2022, and starting September 2022, is the chairman of the audit committee and a member of the compensation committee. He also has served on the board of directors of Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, since March 2019, and is chairman of the audit committee and a member of the compensation and finance committees. Mr. Wills serves as the Chief Financial Officer of Cactus Acquisition Corp (Nasdaq: CCTS), a Special Purpose Acquisition Company (SPAC). Mr. Wills served on the board of directors of Amryt Pharma Plc, a biopharmaceutical company focused on developing and delivering treatments to help improve the lives of patients with rare and orphan diseases, from September 2019 through April 2023, when Amryt was acquired by Chiesi Farmaceutici. Mr. Wills served on the board of trustees and executive committee of The Hun School of Princeton, a college preparatory day and boarding school since 2014, and as its Chairman starting June 2018, to his retirement in June 2023. Mr. Wills served on the board of directors of Caliper Corporation, a psychological assessment and talent development company, since March 2016, and as Chairman from December 2016 to December 2019, when PSI Corporation acquired Caliper. Mr. Wills served as Executive Chairman and Interim Principal Executive Officer of Derma Sciences, Inc., a provider of advanced wound care products, from December 2015 to February 2017, when Derma Sciences was acquired by Integra Lifesciences (Nasdaq: IART). Previously, Mr. Wills served on the board of directors of Derma Sciences as the lead director and chairperson of the audit committee from June 2000 to December 2015, and served as the Chief Financial Officer of Derma Sciences from 1997 to 2000. Mr. Wills served as the President and Chief Operating Officer of Wills, Owens & Baker, P.C., a public accounting firm, from 1991 to 2000. Mr. Wills, a certified public accountant, earned his Bachelor of Science in accounting from West Chester University, and a Master of Science in taxation from Temple University.
Amy Paul

Amy Paul自2013年5月以来担任Derma Sciences的董事。她于2008年退休(在C.R. Bard, Inc.(医疗器械公司)工作26年之后),最近自2003年以来担任国际的集团副总裁。她从1982年到2003年在C.R. Bard, Inc.担任各种职位,包括Bard Access Systems, Inc.的总裁,Bard Endoscopic Technologies的总裁,Bard Ventures的副总裁兼业务经理,Bard Cardiopulmonary Division营销的副总裁,Davol Inc.的营销经理和Davol Inc.的高级产品经理。她是上市公司Viking Systems, Inc.的董事,直到2012年10月它被Conmed Corporation收购,从2010年到2013年是西北高校委员会(Northwest Commission on Colleges and Universities)的专员,从2010年到2012年是Theraclion(在法国,巴黎的私营公司)的董事。她目前服务于威斯敏斯特学院(Westminster College)的总裁创新网络(President's Innovation Network),是上市公司Wright Medical Technologies的董事,在此她是提名,公司治理和合规委员会(Nominating, Governance and Compliance Committee)的主席。她于1973年获得波士顿大学(Boston University)的英语文学学士学位,于1978年获得波士顿大学(Boston University)的工商管理硕士学位。


Amy Paul has served as a director of Derma Sciences since May 2013. Ms. Paul retired in 2008 following a 26-year career with C.R. Bard, Inc., a medical device company, most recently serving as the Group Vice President-International since 2003. She served in various positions at C.R. Bard, Inc. from 1982 to 2003 including President of Bard Access Systems, Inc., President of Bard Endoscopic Technologies, Vice President and Business Manager of Bard Ventures, Vice President of Marketing of Bard Cardiopulmonary Division, Marketing Manager for Davol Inc., and Senior Product Manager for Davol Inc. Ms. Paul was a director of Viking Systems, Inc., a publicly traded company, until October 2012 when it was acquired by Conmed Corporation, was a commissioner of the Northwest Commission on Colleges and Universities from 2010 through 2013 and was a Director of Theraclion from 2010 through 2012 a privately held company in Paris, France. Ms. Paul currently serves on the President’s Innovation Network at Westminster College and is a Director of Wright Medical Technologies, a publicly traded company, for which she chairs the Nominating, Governance and Compliance Committee. Ms. Paul earned a Bachelor of Arts degree in English from Boston University in 1973 and an MBA from Boston University in 1978.
Amy Paul自2013年5月以来担任Derma Sciences的董事。她于2008年退休(在C.R. Bard, Inc.(医疗器械公司)工作26年之后),最近自2003年以来担任国际的集团副总裁。她从1982年到2003年在C.R. Bard, Inc.担任各种职位,包括Bard Access Systems, Inc.的总裁,Bard Endoscopic Technologies的总裁,Bard Ventures的副总裁兼业务经理,Bard Cardiopulmonary Division营销的副总裁,Davol Inc.的营销经理和Davol Inc.的高级产品经理。她是上市公司Viking Systems, Inc.的董事,直到2012年10月它被Conmed Corporation收购,从2010年到2013年是西北高校委员会(Northwest Commission on Colleges and Universities)的专员,从2010年到2012年是Theraclion(在法国,巴黎的私营公司)的董事。她目前服务于威斯敏斯特学院(Westminster College)的总裁创新网络(President's Innovation Network),是上市公司Wright Medical Technologies的董事,在此她是提名,公司治理和合规委员会(Nominating, Governance and Compliance Committee)的主席。她于1973年获得波士顿大学(Boston University)的英语文学学士学位,于1978年获得波士顿大学(Boston University)的工商管理硕士学位。
Amy Paul has served as a director of Derma Sciences since May 2013. Ms. Paul retired in 2008 following a 26-year career with C.R. Bard, Inc., a medical device company, most recently serving as the Group Vice President-International since 2003. She served in various positions at C.R. Bard, Inc. from 1982 to 2003 including President of Bard Access Systems, Inc., President of Bard Endoscopic Technologies, Vice President and Business Manager of Bard Ventures, Vice President of Marketing of Bard Cardiopulmonary Division, Marketing Manager for Davol Inc., and Senior Product Manager for Davol Inc. Ms. Paul was a director of Viking Systems, Inc., a publicly traded company, until October 2012 when it was acquired by Conmed Corporation, was a commissioner of the Northwest Commission on Colleges and Universities from 2010 through 2013 and was a Director of Theraclion from 2010 through 2012 a privately held company in Paris, France. Ms. Paul currently serves on the President’s Innovation Network at Westminster College and is a Director of Wright Medical Technologies, a publicly traded company, for which she chairs the Nominating, Governance and Compliance Committee. Ms. Paul earned a Bachelor of Arts degree in English from Boston University in 1973 and an MBA from Boston University in 1978.

高管简历

中英对照 |  中文 |  英文
John E. Yetter

John E. Yetter,注册会计师,从2013年1月以来担任我们的金融执行副总裁和首席财务官;从2000年8月起,担任我们的副总裁和首席财务官。加入我们之前,John E. Yetter在Bristol-Myers Squibb担任过多个高级财经职务。在加入Bristol-Myers Squibb之前,他在Cooper Industries, Inc.、 Price Waterhouse以及Hulse Manufacturing Company担任过多个财经监督职务。John E. Yetter是美国注册会计师协会(American Institute of Certified Public Accountants)和的成员。1975年,他从马萨诸塞州波士顿的波士顿大学管理学院(Boston College School of Management, Boston)以优等成绩毕业,获得了会计学学士学位。


John E. Yetter has served as our Executive Vice President, Finance and Chief Financial Officer since January 2013 and previously as our Vice President and Chief Financial Officer beginning in August 2000. Prior to joining us, Mr. Yetter held a variety of senior financial positions with Bristol-Myers Squibb Company. Before his association with Bristol-Myers Squibb, he held several supervisory financial positions with Cooper Industries, Inc., Price Waterhouse and Hulse Manufacturing Company. Mr. Yetter is a member of the American Institute of Certified Public Accountants and the New York Society of Certified Public Accountants. He earned a Bachelor of Science in Accounting, magna cum laude, from Boston College School of Management, Boston, Massachusetts in 1975.
John E. Yetter,注册会计师,从2013年1月以来担任我们的金融执行副总裁和首席财务官;从2000年8月起,担任我们的副总裁和首席财务官。加入我们之前,John E. Yetter在Bristol-Myers Squibb担任过多个高级财经职务。在加入Bristol-Myers Squibb之前,他在Cooper Industries, Inc.、 Price Waterhouse以及Hulse Manufacturing Company担任过多个财经监督职务。John E. Yetter是美国注册会计师协会(American Institute of Certified Public Accountants)和的成员。1975年,他从马萨诸塞州波士顿的波士顿大学管理学院(Boston College School of Management, Boston)以优等成绩毕业,获得了会计学学士学位。
John E. Yetter has served as our Executive Vice President, Finance and Chief Financial Officer since January 2013 and previously as our Vice President and Chief Financial Officer beginning in August 2000. Prior to joining us, Mr. Yetter held a variety of senior financial positions with Bristol-Myers Squibb Company. Before his association with Bristol-Myers Squibb, he held several supervisory financial positions with Cooper Industries, Inc., Price Waterhouse and Hulse Manufacturing Company. Mr. Yetter is a member of the American Institute of Certified Public Accountants and the New York Society of Certified Public Accountants. He earned a Bachelor of Science in Accounting, magna cum laude, from Boston College School of Management, Boston, Massachusetts in 1975.
Robert C. Cole

Robert C. Cole,从2013年1月起,担任我们的传统伤口护理集团总裁和公司会计;从2006年5月起,担任我们的销售执行副总裁;从2003年1月到2006年4月,在担任销售执行副总裁之前,他担任我们的销售和营销副总裁。在加入我们之前,从1974年起,Robert C. Cole在B. Braun Medical和其前身公司担任过多个执行销售职务,最近的一个职务是东部地区销售副总裁。Robert C. Cole在1974年,以优等成绩毕业于宾夕法尼亚拉特罗布圣文森特学院(St. Vincent's College, Latrobe, Pennsylvania),获得了生物学学士学位。


Robert C. Cole has served as our Group President, Traditional Wound Care and Corporate Accounts since January 2013 and previously as our Executive Vice President for Sales beginning in May 2006. Prior to his position as Executive Vice President for Sales, he served as our Vice President - Sales and Marketing from January 2003 through April 2006. Prior to joining us, Mr. Cole held a variety of executive sales positions with B. Braun Medical and predecessor firms beginning in 1974 most recently as Vice President, Sales, Eastern Zone. Mr. Cole earned his Bachelor of Science degree in Biology, cum laude, from St. Vincent’s College, Latrobe, Pennsylvania, in 1974.
Robert C. Cole,从2013年1月起,担任我们的传统伤口护理集团总裁和公司会计;从2006年5月起,担任我们的销售执行副总裁;从2003年1月到2006年4月,在担任销售执行副总裁之前,他担任我们的销售和营销副总裁。在加入我们之前,从1974年起,Robert C. Cole在B. Braun Medical和其前身公司担任过多个执行销售职务,最近的一个职务是东部地区销售副总裁。Robert C. Cole在1974年,以优等成绩毕业于宾夕法尼亚拉特罗布圣文森特学院(St. Vincent's College, Latrobe, Pennsylvania),获得了生物学学士学位。
Robert C. Cole has served as our Group President, Traditional Wound Care and Corporate Accounts since January 2013 and previously as our Executive Vice President for Sales beginning in May 2006. Prior to his position as Executive Vice President for Sales, he served as our Vice President - Sales and Marketing from January 2003 through April 2006. Prior to joining us, Mr. Cole held a variety of executive sales positions with B. Braun Medical and predecessor firms beginning in 1974 most recently as Vice President, Sales, Eastern Zone. Mr. Cole earned his Bachelor of Science degree in Biology, cum laude, from St. Vincent’s College, Latrobe, Pennsylvania, in 1974.
Frederic Eigner

Frederic Eigner,从2005年3月起担任我们的运营执行副总裁,我们在加拿大的子公司Derma Sciences Canada Inc.的总经理。在此之前,从2002年8月起,他担任Derma Sciences Canada Inc.的运营副总裁。在被我们收购之前,他于1992年至2002年8月在Dumex Medical Inc.担任过数个职位,并在最近担任其执行副总裁。从1980年到1992年,Frederic Eigner在The Kendall Company担任过多个生产执行官职务。他拥有斯洛文尼亚克拉尼高级技术学校(High Technical School of Kranj, Slovenia)于1975年授予的工业工程学学士学位、斯洛文尼亚马里博尔大学(University of Maribor, Slovenia)于1980年授予的化学工程硕士学位以及加拿大安大略省多伦多大学(University of Toronto, Ontario, Canada)于2000年授予的工商管理学硕士学位。


Frederic Eigner has served as our Executive Vice President, Operations and General Manager of our Canadian subsidiary, Derma Sciences Canada Inc., since March 2005. Previously, beginning in August 2002 he served as Vice President for Operations of Derma Sciences Canada Inc. Prior to its acquisition by us, he held several positions with Dumex Medical Inc. during the period 1992 until August 2002 most recently as Executive Vice President. Prior to his association with Dumex Medical Inc., Mr. Eigner held a variety of executive manufacturing positions with The Kendall Company during the period from 1980 through 1992 most recently as Director of Manufacturing. He earned a Bachelor of Science degree in Industrial Engineering from the High Technical School of Kranj, Slovenia, in 1975 a Master of Science degree in Chemical Engineering from the University of Maribor, Slovenia, in 1980 and a Master of Business Administration degree from the University of Toronto, Ontario, Canada, in 2000.
Frederic Eigner,从2005年3月起担任我们的运营执行副总裁,我们在加拿大的子公司Derma Sciences Canada Inc.的总经理。在此之前,从2002年8月起,他担任Derma Sciences Canada Inc.的运营副总裁。在被我们收购之前,他于1992年至2002年8月在Dumex Medical Inc.担任过数个职位,并在最近担任其执行副总裁。从1980年到1992年,Frederic Eigner在The Kendall Company担任过多个生产执行官职务。他拥有斯洛文尼亚克拉尼高级技术学校(High Technical School of Kranj, Slovenia)于1975年授予的工业工程学学士学位、斯洛文尼亚马里博尔大学(University of Maribor, Slovenia)于1980年授予的化学工程硕士学位以及加拿大安大略省多伦多大学(University of Toronto, Ontario, Canada)于2000年授予的工商管理学硕士学位。
Frederic Eigner has served as our Executive Vice President, Operations and General Manager of our Canadian subsidiary, Derma Sciences Canada Inc., since March 2005. Previously, beginning in August 2002 he served as Vice President for Operations of Derma Sciences Canada Inc. Prior to its acquisition by us, he held several positions with Dumex Medical Inc. during the period 1992 until August 2002 most recently as Executive Vice President. Prior to his association with Dumex Medical Inc., Mr. Eigner held a variety of executive manufacturing positions with The Kendall Company during the period from 1980 through 1992 most recently as Director of Manufacturing. He earned a Bachelor of Science degree in Industrial Engineering from the High Technical School of Kranj, Slovenia, in 1975 a Master of Science degree in Chemical Engineering from the University of Maribor, Slovenia, in 1980 and a Master of Business Administration degree from the University of Toronto, Ontario, Canada, in 2000.
Barry J. Wolfenson

Barry J. Wolfenson,从2013年1月起担任我们高级伤口护理和制药发展的集团总裁。在此之前,从2010年3月到2012年12月,他担任我们全球业务发展和市场营销执行副总裁;从2006年3月到2010年2月,担任我们的营销和业务发展副总裁;从2004年2月到2006年2月,担任我们的市场总监。在加入我们之前,Barry J. Wolfenson从2001年起在Bristol-Myers担任过多个销售和营销职务,并于近期担任Bristol-Myers Squibb ConvaTec division的市场营销经理。在供职于Bristol-Myers Squibb之前,他经营着一个成功的创业企业——Andersen Consulting,并担任其业务经理。Barry J. Wolfenson拥有宾夕法尼亚州兰开斯特市富兰克林与马歇尔学院(Franklin and Marshall College, Lancaster, Pennsylvania)于1989年授予的经济学学士学位,并于2001年获得密歇根州安阿伯市密歇根大学(University of Michigan, Ann Arbor, Michigan)授予的工商管理学硕士学位,是大学优等生。


Barry J. Wolfenson has served as our Group President, Advanced Wound Care and Pharmaceutical Development since January 2013. Effective March 9 2015 Mr. Wolfenson’s title was changed to Group President, Advanced Wound Care. Mr. Wolfenson previously served as our Executive Vice President, Global Business Development and Marketing from March 2010 through December 2012; our Vice President for Marketing and Business Development from March 2006 through February 2010; and our Director of Marketing from February 2004 through February 2006. Prior to joining us, Mr. Wolfenson held a variety of sales and marketing positions with Bristol-Myers Squibb beginning in 2001 most recently as Marketing Manager with the Bristol-Myers Squibb ConvaTec division. Before his association with Bristol-Myers Squibb, he operated a successful entrepreneurial venture and served as an account executive with Andersen Consulting. Mr. Wolfenson earned a Bachelor of Science degree in Economics from Franklin and Marshall College, Lancaster, Pennsylvania, in 1989 and a Master of Business Administration degree, with High Distinction, from the University of Michigan, Ann Arbor, Michigan, in 2001.
Barry J. Wolfenson,从2013年1月起担任我们高级伤口护理和制药发展的集团总裁。在此之前,从2010年3月到2012年12月,他担任我们全球业务发展和市场营销执行副总裁;从2006年3月到2010年2月,担任我们的营销和业务发展副总裁;从2004年2月到2006年2月,担任我们的市场总监。在加入我们之前,Barry J. Wolfenson从2001年起在Bristol-Myers担任过多个销售和营销职务,并于近期担任Bristol-Myers Squibb ConvaTec division的市场营销经理。在供职于Bristol-Myers Squibb之前,他经营着一个成功的创业企业——Andersen Consulting,并担任其业务经理。Barry J. Wolfenson拥有宾夕法尼亚州兰开斯特市富兰克林与马歇尔学院(Franklin and Marshall College, Lancaster, Pennsylvania)于1989年授予的经济学学士学位,并于2001年获得密歇根州安阿伯市密歇根大学(University of Michigan, Ann Arbor, Michigan)授予的工商管理学硕士学位,是大学优等生。
Barry J. Wolfenson has served as our Group President, Advanced Wound Care and Pharmaceutical Development since January 2013. Effective March 9 2015 Mr. Wolfenson’s title was changed to Group President, Advanced Wound Care. Mr. Wolfenson previously served as our Executive Vice President, Global Business Development and Marketing from March 2010 through December 2012; our Vice President for Marketing and Business Development from March 2006 through February 2010; and our Director of Marketing from February 2004 through February 2006. Prior to joining us, Mr. Wolfenson held a variety of sales and marketing positions with Bristol-Myers Squibb beginning in 2001 most recently as Marketing Manager with the Bristol-Myers Squibb ConvaTec division. Before his association with Bristol-Myers Squibb, he operated a successful entrepreneurial venture and served as an account executive with Andersen Consulting. Mr. Wolfenson earned a Bachelor of Science degree in Economics from Franklin and Marshall College, Lancaster, Pennsylvania, in 1989 and a Master of Business Administration degree, with High Distinction, from the University of Michigan, Ann Arbor, Michigan, in 2001.
Stephen T. Wills

Stephen T. Wills,1997年起,担任副总裁、秘书、财务总管、首席财务官;2005年起,担任运营执行副总裁,直到2011年6月被任命为首席运营官、执行副总裁。1997年7月至2000年8月,他还是Derma Sciences的副总裁、首席财务官,这是一个供应伤口、皮肤护理产品的上市公司,目前担任其首席董事。之前,他曾担任Miami International Securities Exchange, LLC的董事、审核委员会主席,这是私营的全电子化的期权和股票交易所,目前仍在开发中;此前,他曾担任上市公司U.S. Helicopter Corp.的董事。1991年至2000年8月,他是Golomb, Wills & Company, P.C。的总裁、首席运营官,这是一个公共会计公司。他是注册会计师,获得West Chester University的会计学士学位、Temple University的税务硕士学位。


Stephen T. Wills,currently serves as the Chief Financial Officer (since 1997), Chief Operating Officer (since 2011), Treasurer and Secretary, of Palatin. Mr. Wills has served on the board of directors of MediWound Ltd. (Nasdaq: MDWD), a biopharmaceutical company focused on treatment in the fields of severe burns, chronic and other hard to heal wounds, since April 2017, and as Chairman from October 2017 until August 2022, and starting September 2022, is the chairman of the audit committee and a member of the compensation committee. He also has served on the board of directors of Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, since March 2019, and is chairman of the audit committee and a member of the compensation and finance committees. Mr. Wills serves as the Chief Financial Officer of Cactus Acquisition Corp (Nasdaq: CCTS), a Special Purpose Acquisition Company (SPAC). Mr. Wills served on the board of directors of Amryt Pharma Plc, a biopharmaceutical company focused on developing and delivering treatments to help improve the lives of patients with rare and orphan diseases, from September 2019 through April 2023, when Amryt was acquired by Chiesi Farmaceutici. Mr. Wills served on the board of trustees and executive committee of The Hun School of Princeton, a college preparatory day and boarding school since 2014, and as its Chairman starting June 2018, to his retirement in June 2023. Mr. Wills served on the board of directors of Caliper Corporation, a psychological assessment and talent development company, since March 2016, and as Chairman from December 2016 to December 2019, when PSI Corporation acquired Caliper. Mr. Wills served as Executive Chairman and Interim Principal Executive Officer of Derma Sciences, Inc., a provider of advanced wound care products, from December 2015 to February 2017, when Derma Sciences was acquired by Integra Lifesciences (Nasdaq: IART). Previously, Mr. Wills served on the board of directors of Derma Sciences as the lead director and chairperson of the audit committee from June 2000 to December 2015, and served as the Chief Financial Officer of Derma Sciences from 1997 to 2000. Mr. Wills served as the President and Chief Operating Officer of Wills, Owens & Baker, P.C., a public accounting firm, from 1991 to 2000. Mr. Wills, a certified public accountant, earned his Bachelor of Science in accounting from West Chester University, and a Master of Science in taxation from Temple University.
Stephen T. Wills,1997年起,担任副总裁、秘书、财务总管、首席财务官;2005年起,担任运营执行副总裁,直到2011年6月被任命为首席运营官、执行副总裁。1997年7月至2000年8月,他还是Derma Sciences的副总裁、首席财务官,这是一个供应伤口、皮肤护理产品的上市公司,目前担任其首席董事。之前,他曾担任Miami International Securities Exchange, LLC的董事、审核委员会主席,这是私营的全电子化的期权和股票交易所,目前仍在开发中;此前,他曾担任上市公司U.S. Helicopter Corp.的董事。1991年至2000年8月,他是Golomb, Wills & Company, P.C。的总裁、首席运营官,这是一个公共会计公司。他是注册会计师,获得West Chester University的会计学士学位、Temple University的税务硕士学位。
Stephen T. Wills,currently serves as the Chief Financial Officer (since 1997), Chief Operating Officer (since 2011), Treasurer and Secretary, of Palatin. Mr. Wills has served on the board of directors of MediWound Ltd. (Nasdaq: MDWD), a biopharmaceutical company focused on treatment in the fields of severe burns, chronic and other hard to heal wounds, since April 2017, and as Chairman from October 2017 until August 2022, and starting September 2022, is the chairman of the audit committee and a member of the compensation committee. He also has served on the board of directors of Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, since March 2019, and is chairman of the audit committee and a member of the compensation and finance committees. Mr. Wills serves as the Chief Financial Officer of Cactus Acquisition Corp (Nasdaq: CCTS), a Special Purpose Acquisition Company (SPAC). Mr. Wills served on the board of directors of Amryt Pharma Plc, a biopharmaceutical company focused on developing and delivering treatments to help improve the lives of patients with rare and orphan diseases, from September 2019 through April 2023, when Amryt was acquired by Chiesi Farmaceutici. Mr. Wills served on the board of trustees and executive committee of The Hun School of Princeton, a college preparatory day and boarding school since 2014, and as its Chairman starting June 2018, to his retirement in June 2023. Mr. Wills served on the board of directors of Caliper Corporation, a psychological assessment and talent development company, since March 2016, and as Chairman from December 2016 to December 2019, when PSI Corporation acquired Caliper. Mr. Wills served as Executive Chairman and Interim Principal Executive Officer of Derma Sciences, Inc., a provider of advanced wound care products, from December 2015 to February 2017, when Derma Sciences was acquired by Integra Lifesciences (Nasdaq: IART). Previously, Mr. Wills served on the board of directors of Derma Sciences as the lead director and chairperson of the audit committee from June 2000 to December 2015, and served as the Chief Financial Officer of Derma Sciences from 1997 to 2000. Mr. Wills served as the President and Chief Operating Officer of Wills, Owens & Baker, P.C., a public accounting firm, from 1991 to 2000. Mr. Wills, a certified public accountant, earned his Bachelor of Science in accounting from West Chester University, and a Master of Science in taxation from Temple University.